Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2012; 11(02): 65-69
DOI: 10.4103/1450-1147.103413
Original Article

18 F-FLT-PET for response evaluation of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with solid tumors

Ingrid Desar
Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
,
Rozemarie Gilles
1   Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
,
Carla van Herpen
Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
,
Anja J. Timmer-Bonte
Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
,
Mireille Cantarini
2   Astra Zeneca, Alderley Park, Macclesfield, UK
,
Winette van der Graaf
Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
,
Wim Oyen
1   Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Selumetinib (AZD6244, ARRY-142886) is a potent, selective, uncompetitive inhibitor of MEK 1 / 2, part of the RAF/MEK/ERK protein kinase signal cascade, which is responsible for tumor. This pilot study was used to explore if 18  F-fluoro-l-thymidine (FLT), a thymidine analogue positron emission tomography (PET) tracer and a surrogate marker for proliferation, can be used as an early predictor of response for patients with solid cancers treated with Selumetinib. FLT-PET scans were performed in four patients at baseline and after 2 weeks of treatment with Selumetinib. FLT uptake in tumors was analyzed qualitatively and quantitatively by measuring standard uptake value (SUV) max in regions of interest (ROI). Results were compared to computed tomography (CT) scans (baseline and after 8 weeks), which were evaluated using the response evaluation criteria in solid tumors (RECIST) 1.0 criteria. One patient with melanoma showed both a qualitative and quantitative decrease in FLT uptake associated with a decrease in sum of longest diameter of 12% RECIST on CT evaluation. Another patient who had colorectal carcinoma (CRC) showed a significant increase in FLT uptake with initially stable, but eventually progressive disease on CT. The other two patients (one with melanoma and one with CRC) showed no significant changes in FLT uptake, whereas CT evaluation showed progressive disease. This is the first report describing changes in FLT-PET in patients receiving Selumetinib. In two patients, changes in FLT uptake as early as after 2 weeks of treatment were consistent with CT results after 8 weeks. Biomarkers to predict and evaluate treatment the outcome of targeted therapies are highly warranted. These initial results need further investigation.

Keywords

F-18 FLT - PET-CT - Selumetinib - treatment response


Publication History

Article published online:
21 May 2022

© 2012. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India